Education Innovation Conference (EIC2018) - London

Dr Fiona Marston CEO (Absynth Biologics ltd)

Bio

Fiona has over 25 years experience in healthcare, biotechnology and venture capital. She was the co-founder and Chief Executive of the anti-infectives company Novacta Biosystems until the end of 2007. Before this Fiona was Chief Executive of Pharminox Limited, Novarticulate BV and Metris Therapeutics Limited. She worked in venture capital for Rothschilds and J&J Development Corporation in the mid-90s specialising in the strategic development and management of early-stage companies. Fiona’s early career was in business development at CRC Technology Limited and at Celltech plc.

Prabhu Mishra CEO and also President -StemMax Research (StemGenn Therapeutics,)

Bio

Prabhu Mishra , CEO & Founder- StemGenn Therapeutics, President – StemMax Research & Therapeutics Pvt Ltd. Co-Founder- Global StemGenn Therapy & Research PVT ltd. Ex- Secretary General – Stem cell society (India) , Founder President – Anti ageing Foundation, Vice President- Indian Stem cell study Group.

Advisor: Regenerative Therapy- IORA, Stem cell committee Head – ISAR Delhi Chapter , Reviewer – Journal of cutaneous and aesthetic surgery. Associate Editor – Indian journal of stem cell Therapy. Collaborator with SumanDeep Vidyapeeth University , InDNA LIFESCIENCES. Member ,International society of Cellular Therapy, American society of cell and Gene Therapy, International society of stem cell Research. Founded- Indian Regenerative and Aesthetic science study group.

Given consultation to more than 15 stem cell facilities. Prabhu Mishra have set up 8 stem cells centre across country and Internationally.

Prabhu Mishra, welcomes you to StemGenn Therapeutics, a leading stem cell therapy & regenerative medicine services company, hurling the stem cell revolution in India. It is dedicated to the development and commercialisation of cellular therapies and stem cell research in India. Prabhu Mishra works to develop strategic alliances and to implement national and international projects for the mission of advancing regenerative medicine and stem cell therapy.

StemGenn Mission is contribute to human health by enabling technologies using Regenerative Medicine. Aims to provide treatment option in Aesthetic Medicine, Anti Ageing , Infertility, Cosmetic Gynaecology , Wellness , Life style Diseases & Auto immune diseases.

StemGenn started world class training module in Stem Cell & Regenerative Medicine , Bio Identical Hormones , Aesthetic Medicine , Cosmetic Gynaecology & Anti Ageing .

Prabhu Mishra works to develop strategic alliances and to implement national and international projects for the mission of advancing regenerative medicine and stem cell therapy. Prabhu’s personal experience with life-changing cellular therapies and adult stem cell transplant programme ignited his passion to be involved with an innovative new area of medicine bringing together the industry leaders in regulatory, science, medicine, safety and ethics via a association model to yield the best possible patient outcomes.  Prabhu participates in the organizational business strategy, membership procurement, marketing, international and domestic conference and event planning/implementation, financial decisions and budgeting. Prabhu works with the GIOSTAR team to develop compelling business plans to optimize strategy, present a competitive edge, and to articulate the client’s competitive position. Prabhu creates financial reports for Executive Summaries such as profit/loss statements which include sales forecasts, personnel and operating costs, break even analysis and cash flow projections.

Specialties Area: Blood Bank & Transfusion Medicine , Cord blood Banking, Stem cells (adipose, dental pulp, peripheral blood, limbal) Plastic Surgery, General Surgery(Abdominal Wall Reconstruction, Hernia Repair, Breast Surgery, Wound Care and Trauma), Orthopedics, Spine , Sports Medicine, Neurosurgery, Trauma, Colon Rectal, Cardiac, Perfusion, Dental, Oral Max , Vascular, BMA, Bone Marrow Aspirate, PRP, Platelet Rich Plasma, Stem Cell, Tissue Regeneration and Regenerative Medicine.

Prof. Mammo Muchie Research Chair In Innovation Studies (Tshwane University Of Technology)

Bio

Professor Mammo Muchie holds a DPhil in Science, Technology, and Innovation for Development (STI&D) from the University of Sussex. UK. He is currently a DST/NRF rated Research Professor at the Faculty of Management Sciences, Tshwane University of Technology, South Africa. He is a fellow of the South African Academy of Sciences and the African Academy of Sciences. He is also currently adjunct Professor at the Adama Science, Technology University, Arsi University, Addis Ababa University and University of Gondar, Ethiopia. He has been senior research associate at the SPMTDC programme and also has become Senior Research Associate at the TMD Centre of Oxford University.

He is collaborating with researchers (DILIC) on the potential research areas of Africa-China industrial high-technology sectors. He has been invited as Associate Faculty professor at Sussex University, UK for the next three years; at the University of Economics in Prague as visiting professor, Jawarahal Nehru University India, Tonji and Shanghai University, China; Honorary Professor Jiaxing University, China, Assistant Professor Amsterdam University, Visiting Professor Carleton College, USA; Principal Lecturer, Middlesex University, Professor, Aalborg University; Part–time Lecturer, Cambridge University; Honorary Professor UNISA. Professor Mammo held various positions globally, including the Director of the Research Programme on Civil Society and African Integration at the then University of Kwa Zulu-Natal; board member at the North Western University, Chengdu, China.

He is currently the chairman of the advisory board of African Talent hub of the Community Interest Company (registration no.10461990) to raise funds for making Africa the talent, innovation, entrepreneurship, creativity and knowledge hub of the world. He has been appointed as special distinguished advisor to the Africa Union’s Student Council and a mentor for the African Entrepreneurship award. He has initiated the African Unity for Renaissance and Knowledge Exchange series of conferences since the last six years. He is a founding scientific advisor to ´the African Solar network, founding chairman of the Network of Ethiopian scholars. He has lead the SIDA, Sweden funded research on engineering design and on transformative innovation for African integrated development and educate on public media to speed up the creation of innovative and renascent Africa. He is also a co-founding member of the Nano Technology Institute in TUT leading the innovation side of the research.

Prof. Souvik Bhattacharyya Senior Professor & Vice - Chancellor (BITS Pilani)

Bio

Souvik Bhattacharyya graduated from Jadavpur University, Kolkata with a Bachelor’s degree (1981), MS (1985) from University of Cincinnati, USA and PhD from Texas A&M University (1991), USA – all in Mechanical Engineering specializing in thermal sciences. After a post-doctoral research stint at TexasA&M, he joined the faculty of IIT Kharagpur in 1991 where he was Dean (Students’ Affairs) during 2009-2012 and has been a Professor of Mechanical Engineering since 2003, Professor (HAG) since 2009. He also held faculty position at University of Canterbury, Christchurch, New Zealand during 1998-2000. He served as the Vice-Chancellor of Jadavpur University, Kolkata during August 2012–October 2013 and as Deputy Director of IIT Kharagpur during 2013-2016. Currently he is the Vice-Chancellor of BITS Pilani. Prof Bhattacharyya is a Member of the Research Council of CSIR-CGCRI, the General Council & Executive Board of ISM, Dhanbad and the Civil & Mechanical Engineering Project Advisory Committee (PAC) of SERB, DST.

Dr Bhattacharyya has been on the Editorial Boards of International Journal of Power and Energy Systems and Journal of Nano Energy and Power Research. He is an Associate Editor of the international journal Alternative Energy and was on the Editorial Board of Energy Conversion and Management during 2007-2013. He was a member of the Committee on Fast track scheme for young scientists, DST during 2007 –2012. His research interests include heat transfer enhancement, thermodynamic optimization, energy engineering, natural refrigerant based transcritical heating-cooling systems, and natural circulation loops. A recipient of ASHRAE Best Paper Award, Dr Bhattacharyya has published about 220 research articles in indexed international journals and conference proceedings and is a co-author of the celebrated Heat Transfer text with J P Holman.

He is a Fellow of the Indian National Academy of Engineering (INAE), National Academy of Science, India (NASI) and WB Academy of Science & Technology.

He is known as an adored teacher among the students of IIT Kharagpur and was the first recipient of the Outstanding Teacher Award of Indian National Academy of Engineering in its inaugural year in 2013.

Professor Sir Malcolm Grant ()

Bio

Professor Sir Malcolm Grant , CBE, FAcSS is the Chairman of NHS England, formerly known as the NHS Commissioning Board. He is also a barrister and academic lawyer.

Grant was appointed as chair of the newly formed NHS Commissioning Board in 2011 by the Secretary of State for Health, Andrew Lansley. He was previously the ninth President and Provost of University College London – the head as well as principal academic and administrative officer of the university – for over a decade from 2003 until 2013. He is the current Chancellor of the University of York.

In August 2003, Grant left the University of Cambridge to become Provost and President of University College London.

In 2004, Grant launched ‘The Campaign for UCL’. The campaign was designed to generate 300 million pounds of extra funding for the university, to expand facilities and provide for new research initiatives. The appeal will also fund an ear institute, a spinal repair unit and an institute for women’s health. Fifty million pounds of the targeted funds will provide support for students, in the form of bursaries, scholarships, and post-doctoral fellowships. It was the biggest ever fundraising target set by a university in the United Kingdom, until Cambridge set a £1 billion target for its 800-year anniversary followed by the highest ever £3 billion target set by University of Oxford through the Oxford thinking campaign.

Grant said of the ‘Campaign’:

“I have heard it suggested that the concept of philanthropy is somehow alien to the national psyche, and that asking for money is not the British thing to do. This is, frankly, nonsense. Most of our leading universities owe their origins to philanthropy. Without the generosity of our founding fathers, UCL would never have seen the light of day back in 1826. This campaign will enable UCL, a real British success story, to enjoy the kind of resources to enable us to compete with the world’s very best academic institutions”

— Interview with BBC News, 2004

In 2005, on an invitation from The Cheese Grater, he agreed to shave off his moustache if UCL students raised £1500 for Comic Relief, on Red Nose Day. Unfortunately for his moustache — of 33 years — students and staff duly donated over £2,000. However, it has since regrown.

In 2006, he spoke out against the Israel university boycotts by the Association of University Lecturers (now the Universities Colleges Union). In 2006, Grant also controversially stated that European students had better English skills than many British students.

In 2007, Grant said the achievement and academic gap between male and female students was widening. Since 1998, 313,259 more women than men have made university applications. Malcolm Grant said, “the trend indicated a big fall in the number of university-educated men”.

In January 2007, he argued that the entire nationwide university approach to funding needed a different approach. In regard to UCL’s need for additional funding, he stated the reasons in an interview with the BBC:

“”To provide world-class research – through discovery, invention and creativity – and to convey the excitement of it to able young minds.”

— Interview with BBC News, 2007

In June 2007, in response to legal threats from Alan Lakin, husband of a purveyor of herbal remedies, Grant required Professor David Colquhoun to remove his website, “Improbable Science” from university computers. An outcry from the scientific community ensued, and Grant reconsidered, inviting Dr. Colquhoun to bring the site back to UCL once it had been edited for libel.

In December 2011, Grant became the first UCL Provost to be challenged by ‘a vote of No Confidence’ by UCL Union, the representative body of UCL students, following his appointment as chair of the NHS Commissioning Board. However this was deemed unconstitutional.^{[citation needed]} As a result, the matter was passed to a referendum in which the students of UCL voted in confidence of Grant by 1699 votes to 1185, with 391 abstentions.

Patricia Hewitt CHAIR (UK INDIA BUSINESS COUNCIL)

Bio

Patricia Hewitt is the Chair of the UK India Business Council (UKIBC), the premier business-to-business network that works with the British Government to promote bilateral trade between the UK and India.

Patricia Hewitt had a long and distinguished career in politics and government, including as the longest-serving Secretary of State for Trade and Industry in the last fifty years. In that role, she made India her top international priority, believing – as she said in 2002 – that India was rapidly becoming ‘the world’s most exciting knowledge-driven economy’. She also served in Tony Blair’s government as Cabinet Minister for Women (2001 – 2005) and Secretary of State for Health (2005 – 2007). Between 1997 and 2010, Patricia was Labour MP for Leicester West and continues to have close ties with the city and its large British Asian community.

Patricia is a non-executive director of EuroTunnel, a member of the International Advisory Board of Sutherland Global Services and a senior adviser to FTI Consulting. She was for many years Senior Independent Director of BT, where she chaired the remuneration and pensions committees, and a member of the UK government’s Asia Task Force. She is also a member of the UK India Round Table.

For the last six years, Patricia has been an active supporter of Katha, a ‘profit for all’ social enterprise that is transforming the lives of children and their families in Delhi’s slums. She chairs the donor consortium established by the British Asian Trust – one of the Prince of Wales’s Trusts – to support Katha’s work.

In October 2014, Patricia was selected by the British Government to receive the first Dadabhai Naoroji award to recognise her contribution to economic ties between the UK and India.

Born in Australia, Patricia took her undergraduate degree at Cambridge University, and has been awarded an MA by both Cambridge and Oxford. She is an Honorary Associate of Newnham College, Cambridge, an Honorary Doctor of De Montfort University and an Honorary Fellow of the London Business School.

Patricia’s husband, William Birtles, has recently retired from a long career as a barrister and senior judge at the Mayor’s and City of London Court. They have a daughter and a son, both in their 20’s. In her spare time, Patricia enjoys reading, music, theatre and gardening. Although her efforts to learn Hindi have not been very successful, she wowed the Vibrant Gujarat summit in January 2013 with her speech in Gujarati!

Harriet Fear Chief Executive (One Nucleus)

Bio

Harriet Fear joined One Nucleus (formerly ERBI) as CEO in February 2009. She previously worked as a Diplomat with the British Foreign Office for 21 years serving in over 17 countries around the globe. Half her career was spent in the commercial field, latterly heading UK Trade & Investments national life sciences trade team for over 5 years.

She was attracted to the role at One Nucleus because she wanted to spend time helping companies maximise their competitiveness and to lead a team which already had an excellent reputation. Since her arrival at One Nucleus, the company has redefined its membership (now life science and healthcare, not only biotech), formed strong and strategic relations with like minded US counterparts for the benefit of members and merged ERBI with London Biotechnology Network to enhance the offer to members and create a stronger critical mass on the international stage.

One Nucleus is the largest membership organisation in Europe. A not-for-profit private company, it has over 450 members including pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.

The One Nucleus mission is to maximise the global competitiveness of its members. For their science and technology-based members, this means being global leaders in the research, development and commercialisation of healthcare innovations that radically improve the quality of people’s lives around the world. For their business and professional services members, it means delivering exceptional services that significantly enhance the business performance of their clients.

Harriet Fear has accepted the Prime Ministers invitation to continue in her UK Business Ambassador role for a further two years to 2017. She continues to be Chief Executive of One Nucleus – her first priority and passion. By accepting this invitation, Harriet has agreed to undertake, in the margins of her personal or business travel, a programme of activities developed by and with the Government until July 2017. This could include for example, hosting a reception in a country she is travelling to in order to highlight UK expertise in the life science and healthcare sector, briefing UK Ministers and HM Ambassadors on key business priorities and interests as they might arise; meeting overseas Ministers and inward missions; and providing insights into how UK Trade & Investment can better deliver for business.

Anil Wali Managing Director (FITT, IIT DELHI)

Bio

Dr. Anil Wali is currently the MD at Foundation for Innovation and Technology Transfer (FITT) – an autonomous industry interface organization of IIT Delhi. He is managing technologies and driving innovations and enterprise at the academia besides looking at issues of concern to SMEs. He has worked in chemical industry for 19 years before taking up the present position. Besides several publications, patents and reports to his credit, he has a strategic customer and quality orientation, and brings a practical perspective to solving technical problems. He is also called upon to deliberate and participate in the area of clean technology and sustainability. His multifaceted experience towards technology innovation and management, industry partnership, project issues, entrepreneurship, IPR, education, training, etc is sought for advice / association with several committees and programmes. He is an IIT Delhi Doctorate.

Dr. Anil Wali at Foundation for Innovation and Technology Transfer (FITT) believes that FIIT is an industrial interface organization, established at the Indian Institute of Technology Delhi (IIT Delhi) as a Registered Society on 9th July 1992. Dr NC Nigam was the founding Chairman of FITT, and Dr AK Sengupta was the first full-time Managing Director. IIT Delhi’s Review Committee Report -1986, recommended the setting up of an industrial foundation to enhance the programmes of interaction and collaboration between IIT and industry. To implement this recommendation the Institute took up this initiative, with a seed grant received from government at that time, which, led to the setting up of FITT.

FITT aims to be an effective Interface with the Industry to foster, promote and sustain commercialization of Science and Technology in the Institute for mutual benefits. For over twenty years now, FITT has been an interface between the Institute and the industry and has been devising innovative ways to create partnerships and linkages with business and community to enable knowledge transfer for common good. The team at FITT and academicians from IIT Delhi has been largely responsible for the successful outreach efforts including extensive S&T collaborations.

S D Ravetkar Executive Director (Serum Institute of India Limited)

Bio

Dr. S.D. Ravetkar is an Executive Director with Serum Institute of India Ltd. Apart from his Doctorate he holds degrees in Management and Finance. He has authored various research articles in national and international journals. He is also on advisory board of various national and international organizations and journals. He has more than 43 years techno-commercial experience in biotech industry in various areas like QC, production, projects planning & research. At present his major responsibility is manufacturing of Bacterial combination vaccines mainly Pentavalent and Hexavalent vaccine. He has extensively worked on microbial and bioengineering aspects of vaccinology and also has got expertise on technology transfer. He has widely traveled worldwide. He is listed amongst 15 influential figures in the Asian Vaccine Industry.

Dr S D Ravetkar, Executive Director, Serum Institute of India says that the company has put programme in place to achieve the ambitious plan to offer new vaccines

Serum Institute of India Ltd., is the worlds no. 1 producer of Diphtheria, Tetanus, Pertussis, HIB, BCG, Hepatitis B, Measles, Mumps, Rubella vaccines. It is estimated that about 60% of the children in the world receive at least one vaccine manufactured by Serum Institute of India Ltd.

Key focus in the coming year will be enhancing further capacities of above vaccines for which state of art plants are under various stages of completion. The growth has its own problems and challenges. Planned programme has been put in place for handling these issues.

Major thrust is also given on further strengthening quality systems by adding Process Analytical Technology (PAT) in various stages of manufacture of vaccines. More focus is given on incremental innovation than only on disruptive innovation. The technical team building by establishment of new training center is given major thrust.

Serum is also working with various Universities and Research Institutions in country and overseas, in Europe and U.S. to leverage advantage of mutual strengths in knowledge building. The development of critical knowledge mass is thus at center of various activities.

With robust pipeline of various newer vaccines in offing structured programme is carried to reduce time to market. Products on the horizon are many like Rota and Pnemococcus and HPV vaccines. This in itself is a gigantic task of putting new R & D incubators and going through entire process of germination of idea till commercialization.

Innovation is also being implemented in supplying various new vaccine administration systems and for effective measurement thereby validation of cold chain management.

These efforts will help make vaccines available at affordable cost to infant population in world. With acquisition of Bilthoven Biologicals in Netherlands Serum Institute of India Ltd., is looking for entry in Western regulated markets, In years to come as our vaccines are already manufactured in world class environment confirming to International FDA.

Kartik Kumaramangalam CHIEF OF GLOBAL PRODUCTS AND SERVICES (MEDGENOME)

Bio

Kartik Kumaramangalam has worked with multiple high tech startups in his career as an investor and early stage co-founder including Webex (acquired by Cisco) where he was an early founding employee. He has worked in private equity consulting at Boston Consulting Group in New York, and has been a hands on venture capital investor in several successful early stage technology companies in the US and India. Kartik’s undergraduate and master’s degrees are in Astrophysics undertaking research in solar neutrinos at Oxford University, before switching fields and completing his PhD at the London School of Economics as an Interdisciplinary Scholar for his applied mathematical research on scientific labor markets. He is currently also a Visiting Fellow at MIT.

Kartik Kumaramangalam is an active investor and advisor to start-ups and investment projects in Singapore, India and the US. He has previously worked at Boston Consulting Group in New York, been an early employee at WebEx (acquired by Cisco), advised the organization of His Holiness the Dalai Lama on economic policy and was a researcher on a Nobel Prize winning experiment in Astrophysics at Oxford University.

Kartik Kumaramangalam is also a Fellow at MIT and has taught and done research at MIT, London School of Economics and London Business School on the economics of intellectual property and tech driven economic growth. Kartik completed his PhD at the London School of Economics as an Interdisciplinary Scholar winning the Academy of Management Award for his research on scientific labor markets and the economics of ideas. He first trained as an an Astrophysicist specializing in solar neutrino physics as an undergraduate and graduate student at the University of Sussex and the University of Paris.

Kartik’s commitment to economic development comes from a strong background in public service in India with family members who have served as the Governor of Maharashtra, Chief Minister of Madras Presidency, Chief of the Indian Army, Cofounder of Air India (the national carrier) and Cabinet Ministers for Law, Education, Company Affairs, Power, Science, Technology, Coal and Mines.

.

Jonathan Tobin PRINCIPAL (HEALTHCARE VENTURES)

Bio

Jonathan Tobin joined Imperial Innovations in 2011 and specialises in therapeutics and diagnostics investments. He is a board director with antibacterial drug discovery company Auspherix, and diagnostics companies Abingdon Health and Molecular Vision, and a board observer with Cell Medica and Psioxus. Prior to joining Imperial Innovations he worked at MRC Technology, sourcing and evaluating new opportunities for small molecule and antibody drug discovery worldwide. He has a PhD in molecular medicine from UCL, and undertook post-doctoral research at the Cancer Research UK LRI. Jonathan has a First Class degree in Biology from Oxford University and an MBA with Distinction from Imperial College.

Jonathan Tobin is a life science specialist with experience of early and later stage venture capital deals, specialised in therapeutics and diagnostics. Board director of two specialist diagnostics companies and one drug discovery company, board observer of two biotechs and one molecular diagnostics company.

Drug discovery and business development experience; strong science background (PhD, post-doc, ten publications plus book, and numerous scientific awards and scholarships; MBA with Distinction from Imperial College; First Class degree in Biology from Oxford University.

Jonathan Tobin is a non executive director at artios and Artios is developing inhibitors of DNA Damage Repair enzymes to selectively kill cancer cells through a concept known as ‘synthetic lethality’. This has been demonstrated with the recent success of PARP inhibitors in clinical studies, and the launch of Lynparza™ (olaparib; AstraZeneca). DDR targeted products have the potential to be used in combination with other cancer agents to help prevent cancers from reoccuring.

Artios has in-licensed its lead DDR programme, PolƟ, from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK) and continues to work with CRT and other experts in the field to build its pipeline of novel DDR programmes.

In September 2016, Artios raised a £25m Series A from a syndicate including SV Life Sciences, Arix Bioscience, Imperial Innovations, Merck Ventures, Abbvie Ventures, and Sixth Element Capital.

Kaushik D. Deb Director/ CEO (DiponEd BioIntelligence)

Bio

Dr. Kaushik D. Deb, a Heath Care Biotechnology Professional working on developing solutions to unmet medical needs and personalized precision therapies. Developed technology platforms for commercialization and out licensing. Also interested in Rural health care and Clinics. DiponEd is a P4M company (preventive, predictive, participatory and personalized medicine). Merisis Therapeutics – is a fully owned SBU of DiponEd and is involved in the (R&D) development and commercialization of US FDA etc compliant cell processing units, modular clean rooms, BMT / HSCT units, Celluar Therapeutics, Immunotherapies in cancer/ pain/ allergy/ autoimmunity etc, Biologicals, Biosimilars and 3rd Generation Implantable devises and Biomaterials. Also researches in nanobiotechnology, directed stem cell trafficking technologies and integrating Regenerative and Complementary medicine. We work as technology service providers to Corporate Hospitals, Not for profit organizations and Clinics treating Unmet and No-Option medical Conditions.

Dr. Kaushik D. Deb is the founder and director of DiponEd and DiponEd is a P4M company (preventive, predictive, participatory and personalized medicine).

Merisis Therapeutics – is a fully owned SBU of DiponEd and is involved in the (R&D) development and commercialization of US FDA etc compliant cell processing units, modular clean rooms, BMT / HSCT units, Celluar Therapeutics, Immunotherapies in cancer/ pain/ allergy/ autoimmunity etc, Biologicals, Biosimilars and 3rd Generation Implantable devises and Biomaterials. Also researches in nanobiotechnology, directed stem cell trafficking technologies and integrating Regenerative and Complementary medicine. We work as technology service providers to Corporate Hospitals, Not for profit organizations and Clinics treating Unmet and No-Option medical Conditions.

The other activities of DiponEd are related to development of personalized solutions in cell based cosmetics, antiaging, wellness, sports medicine and advanced nanotechnology based FMCG and OTC personal health care products.

Shawn Manning Managing Director and Founder (Akesios Associates Limited)

Bio

Dr Shawn Manning is a Managing Director with Outcome Capital and manages its European operations in London. Outcome Capital is an independent investment banking firm committed to enhancing the corporate and shareholder value of innovative life science companies. Prior to joining Outcome Capital Manning founded Akesios Associates, a specialist advisory firm providing financial strategy, representation and commercial development advice to Life Science companies, with a current focus on IPOs, M&A and portfolio strategy. He has a keen interest in strategy, modelling and outcome optimisation, with a particular focus on oncology, neurology, antibodies, vaccines and the potential strategies impacting the transmission of infectious disease.

Dr Shawn Manning has over 25 years of international Life Sciences experience, including over 12 years as a rated equity analyst (with Dresdner Kleinwort Benson, SG-Cowen/ Société Generale, Bridgewell/ Landsbanki and Singer Capital Markets), covering ‘Big Pharma’, speciality/emerging pharmaceutical, and biotechnology stocks. Over 2006-2012 he helped develop one of the City of London’s leading Life Science Corporate Advisory franchises, his research and advice supporting the raising of over £400m in new funding for Life Science companies. Before entering the City, Manning spent 5 years consulting to the pharmaceutical industry, and managing Datamonitor’s Healthcare practice. In this capacity he worked alongside major European, US and Japanese pharmaceutical companies, leading consultancy projects focusing primarily on strategic product positioning, including portfolio, opportunity and pricing analysis. Manning originally specialised in infectious disease, and holds a Doctorate from the University of Oxford (Hertford College), and a BSc (Hons) and ARCS from Imperial College, London. He is a Fellow of the Royal Society of Medicine, a member of OBN’s Advisory Board and Chairman of OBN’s investment Special Interest Group (iSIG).

Manning is Managing Director at Outcome Capital LLP is a multifaceted technology and life sciences investment banking firm that provides middle-market growth companies with an innovative client-specific approach to private equity and merger and acquisition advisory services. We are passionate about innovation with a mission to facilitate significant positive impact on our companies. We are interested in companies that possess a portfolio of transformative assets, a bold vision and a desire to achieve excellence. We take pride in our ability to enhance value and assist our clients with aligning business objectives with strategic opportunities and transactional expertise.

Carl Sterritt Founder & CEO (Shield Therapeutics)

Bio

Carl Sterritt, with approximately 20 years’ of management and executive level experience in pharmaceutical development and commercialisation in both large and small company settings, Carl has led the Company as its CEO since he co-founded the Group in 2008 together with Dr.Christian Schweiger.

Carl Sterritt held senior management roles at United Therapeutics and Encysive Pharmaceuticals, working on innovative therapies for the treatment of pulmonary arterial hypertension. Carl joined United Therapeutics to establish the company’s European operations in preparation for the marketing approval of Remodulin®, running the subsidiary for six years. In collaboration with physicians in Germany, he was responsible for and holds patents related to United Therapeutics’ decision to develop and commercialise treprostinil; now successfully commercialised in the US as Tyvaso™. Carl was instrumental in the successful commercial launch of Thelin™ and the rapid growth of Encysive’s European operations. Carl founded the Group after Encysive was acquired by Pfizer Inc. for more than $300m.

Since founding Shield Therapeutics plc – a successful and growing specialty pharmaceutical company commercialising novel prescription therapies – Carl has raised close to £70m and led the team that has successfully developed Shield’s two leading assets, Feraccru® and PT20, recently resulting in the approval of Feraccru and completion of Shield’s IPO on the LSE. During this time Shield has also taken PT20 – a treatment for hyperphosphataemia – through a 1st pivotal study, leaving one study to be completed before a marketing authorisation application.

With an under/postgraduate background in life sciences and an MBA from Henley, Carl has approx. 20 years of experience in pharma. Trained in the large pharma environment, he quickly moved into orphan and specialty medicines, working for United Therapeutics as a core member of the Company’s commercialisation team that launched Remodulin® in the USA, after which he established and led the company’s European operations for 6 years. In collaboration with physicians in Germany, he was responsible for and holds patents related to the development and commercialisation of an inhaled form of treprostinil – now commercialised as Tyvaso™. This was followed by a period at Encysive Pharmaceuticals, leading European commercial operations and delivering the successful launch of Thelin™ another treatment for pulmonary arterial hypertension. The company was acquired by Pfizer for over $300m in 2008, following which Carl left, eventually establishing Shield Therapeutics.

A creative, lateral thinker with proven entrepreneurial flair and a clear record of delivering shareholder value. Key strengths include business leadership experience, creation and delivery of effective business strategy, as well as effective communication and relationship building capabilities.

Outside of work Carl enjoys spending time with his family, socialising and participating in or watching a variety of sports.

Patrick Baddeley Corporate Partner (Penningtons Manches LLP)

Bio

Patrick Baddeley a partner in our Oxford corporate team and specialise in a range of corporate transactions including mergers and acquisitions, funding rounds, joint ventures and reorganisations, plus non-transactional advice in relation to corporate constitutional issues.

Many of my clients are technology businesses, particularly in the life sciences industry. I am a member of the firm’s technology and life sciences group and I sit on the Advisory Board of OBN, the UK’s leading membership organisation which supports the UK’s emerging life science companies.

I am also highly experienced in the design and implementation of share based incentives for employees of corporate clients. I am a member of the Share Plan Lawyers group. I have a long-standing interest in India and am a member of the firm’s India group.

Penningtons Manches LLP is a leading UK law firm which provides high quality legal advice tailored to the needs of both businesses and individuals. With offices in the City of London, Basingstoke, Cambridge, Godalming, Guildford, Oxford and Reading, as well as in San Francisco, it has 115 partners and over 600 people in total. It aims to address the specific objectives of each client through its broad market insight and technical expertise, and offers a personal service founded on a strong team ethic.

The firm has established a strong reputation in a variety of sectors including technology, life sciences, education, social housing, retail and international wealth. The main areas of legal services provided are real estate, dispute resolution, corporate and commercial, private client and family.

Clients range from owner managed businesses and start-ups to multi-national corporations, public companies, professional partnerships, banks and financial institutions. The practice’s commitment to excellence is backed by a track record which dates back 300 years.

Penningtons Manches has a broad international focus and provides an integrated service for corporates, individuals and their family members wherever they live or do business. Many of its lawyers play leading roles in a range of international bodies.

Patrick Baddeley, a Penningtons Manches corporate partner, acted for Enterprise Therapeutics, a company formed in May 2014 and based at the Sussex Innovation Centre, University of Sussex. Patrick specialises in the life sciences industry and sits on the Advisory Board of OBN, the UK’s leading membership organisation which supports the UK’s emerging life science companies.

Enterprise Therapeutics’ focus is the discovery of novel disease modifying medications that target key drivers of respiratory disease pathology and progression in cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma. These include targeting the underlying mechanisms of mucus congestion and lung dysfunction.

The additional funding will consolidate and accelerate the drug discovery and target identification programs initiated by the company earlier in 2015.

Ravi Sodha Business Development (Actelion Pharma)

Bio

Ravi Sodha studied in the UK obtaining B.Sc. in Pharmacology, Ph.D. and MBA. He spent several years in Research (London University, Zurich University Hospitals, Ciba Geigy Basel), Clinical Development (SmithKline Beecham) and Sales & Marketing (Novartis). In 1999 Ravi moved to Business Development & Licensing at Novartis, where he spent 8 years in various functions and therapeutic areas. His last responsibility at Novartis was Alliance Management for a Business Franchise and Asia-based job rotation for Business Development activities in the emerging markets, including India, China, Korea and Taiwan. Ravi joined Actelion Pharma Switzerland in 2008 as Senior Director, Business Development, where his responsibilities include structuring and negotiating licensing deals across several therapeutic areas. Ravi has three women in his life, and enjoys cooking, soccer (from the comforts of his arm chair), and spiritual reading.

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical need. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma. Founded in late 1997, with now over 2,500 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI). All trademarks are legally protected.

Erik D. Lazar Director (Transatlantic Law International)

Bio

Erik founded Transatlantic Law International in London in 2001 after more than 15 years of international legal and management experience, including in European General Counsel positions for Fortune 50 companies in Brussels and Luxembourg, where he was responsible for all legal aspects of European operations.

Transatlantic has grown under his direction from an original 15 country presence in Europe to a global business law service, serving primarily Fortune 500 companies in multiple countries worldwide.

Erik specializes in global M&A, restructuring, management of cross-border projects, international transactions, global labor and employment law, antitrust, and commercial agreements.

In M&A he has completed or negotiated over 80 major transactions with a deal value of more than $5 billion in every European country and in Asia since 1992, ranging from mid-cap single country acquisitions to billion-dollar cross border acquisitions and joint ventures.

Prior to moving to Europe in 1991, Erik worked as a corporate and litigation lawyer in leading US law firms in Boston and New York.

He has lectured extensively before bar associations and corporate groups in the United States and in Europe on topics including European M&A, corporate governance, distribution and agency agreements, antitrust and compliance programs, and key issues in cross-border movement of executives, as well as global non-competition agreements, among other matters.

He is also senior outside advisor to a number of Fortune 500 companies on executive labor and employment issues including all legal aspects of executive contracts and cross-border movement of executives among his other areas of practice.

He is an honors graduate of Yale University and of the University of California, Hastings College of the Law, where he edited the Communications and Entertainment Law Journal (Comm/Ent), and is a member of the bars of New York and Massachusetts. He speaks French and German and resides in London.

Dr. Virander Paul Deputy High Commissioner (High Commission of India)

Bio

Virander Paul joined the Indian Foreign Service in 1991. Prior to his assignment as Deputy High Commissioner of India in London, he was Minister(Press) at the Indian Embassy in Washington D.C. Earlier, he has held diplomatic assignments in Indian Missions in Almaty, Vladivostok, Rome, St. Petersburg and Moscow. At the Ministry of External Affairs Headquarters, he has served in Europe East and Americas Divisions. He served as Director in the Prime Minister’s Office during 2007-2010. He holds a medical degree from All India Institute of Medical Sciences, New Delhi.

The areas of potential collaboration between the UK and India were highlighted during the recent visit of the Indian Prime Minister, Mr. Narendra Modi, to the UK.

The UK has a multiplicity of strengths across sectors and is well placed to engage with the ‘Make in India’ initiative.

Dr. Paul added another development is that Indian individuals states are coming to the UK to collaborate and competing with each other. Already 4 states have come so far such as Rajasthan, West Bengal, Odisha and Andhra Pradesh.

On some of the concerns such as more talk and little results, Dr. Paul explained that is short sighted view. He added during last 15 months alone FDI in India has increased by 29%. India is a big country and it may take some time before results show up.

Dr. Virander Paul finally summed up his thought saying India has come a long way from Red Tape to Red Carpet.

First Secretary, T Ajungla Jamir presented Make in India presentation, the idea of 100 smart city project in India with minimum pollution and max recycling.

Dr. Virander Paul, Deputy high commissioner of India to the UK highlighted that

“Fundamentals of Indian economy remain strong and Make in India is very popular brand now. Make in India is not a single stand-alone initiative but many additional projects such as Digital India, Industrial corridor also along with it. These initiatives are all interconnected and feed into each other”.

Funke Abimbola GENERAL COUNSEL & COMPANY SECRETARY (ROCHE (UK & IRELAND))

Bio

FUNKE ABIMBOLA is Managing Counsel (UK & Ireland), UK Data Privacy Officer and UK Company Secretary for Roche, leading the legal team that supports Roche’s pharmaceutical operations in the UK, Ireland, Malta and Gibraltar. She also has a commercial role as England Deployment Lead on a high priority, Roche market access project.

Roche is the world’s largest biotech company.

A practising solicitor for almost 15 years, Funke graduated with an honours degree in law from Newcastle University in 1994. She is qualified to practice law both in Nigeria and in England & Wales.

She is a recognised legal expert within the UK life sciences sector, has received multiple awards and other recognitions for her work and is listed in several international legal directories as an expert in her field.

Importantly, Funke is a notable diversity champion and campaigner within the UK legal industry and has received awards and other recognitions for her diversity work, all of which is done in her spare time on a voluntary basis.

A renowned public speaker, she speaks regularly at legal and diversity conferences in the UK and abroad. She speaks to and advises state school students as part of Speakers for Schools and also supports University students as a Professional Ambassador for Aspiring Solicitors, an organisation devoted to breaking down entry-level barriers for future solicitors from under-represented groups. She is a champion and regular speaker for WILL (Women in Law London), the largest network supporting pre-partnership women solicitors working in private practice and in-house. In addition, she established Women Leaders in Life Sciences law, what is believed to be the first international network dedicated to supporting the pipeline of female lawyer/leaders working within the life sciences industry. She is also personally sponsoring a research-based report on the social mobility issues within the legal profession, due to launch in September 2015.

She is an experienced and expert mentor and sponsor, especially to female and BME students and solicitors. As one of the UK’s leading female pioneers in law, she was recently appointed as a Professional Champion to the First 100 Years project, a ground-breaking project dedicated to building up a digital library celebrating 100 years of female lawyers in the UK.

A proud working mother to a 12 year old son, Funke juggles the demands of her career with home life and advises working mothers on how best to achieve the elusive work/life balance.

Funke is passionate about the law, diversity, education and the healthcare sector. She is also a keen fundraiser for various charities including Cancer Research UK and has twice served as a school governor and a board director.

Ajay Agrawal Managing Director Europe (Ignite Capital Partners, Inc.)

Bio

Dr. Ajay Agrawal, Ph.D., serves as the Managing Director of the Worldwide organization of collaborations in the pharmaceutical industry, London and Director of business development at Lipoxen Plc, AIM-listed company, in London. Dr. Agrawal serves as a Director of business development at Almac Sciences UK and a Special Advisor on healthcare for commonwealth British council, London. He served as the Head of Business Development for Lipoxen Plc (now Xenetic Biosciences, Inc.) since August 2008. Dr. Agrawal has extensive experience in the biotech & pharma industry worldwide. Dr. Agrawal has almost 20 years’ experience in the biotech and pharmaceutical industry worldwide. He founded PolyMASC Pharmaceuticals plc in 1995. Dr. Agrawal is an entrepreneur and advisor to the number of companies worldwide. He serves on the Editorial Advisory Board of four international biotechnology journals from the USA. He serves as a Director of Manipal Acunova Limited. He serves on the Board of Directors of Clinovo Ltd UK. Dr. Agrawal serves on the editorial advisory board of four international pharmaceutical journals from the USA. Dr. Agrawal served as a Non-Executive Director of ImmuPharma plc from April 27, 2007 to October 23, 2015. He serves on the editorial advisory board of three international trade journals, Current Drug Delivery, Infectious Disorders- Drug Targets and Recent Patents on Drug Delivery and Formulation, Bentham Press, California, USA. Dr. Agrawal has been a consultant to a number of companies in the sector, including Genovac GmbH (Germany), Qiagen (Germany), Aldevron (USA), PHT Pharma (Italy) and Karo Bio (Sweden). He holds a PhD in Chemistry and has conducted his post-doctoral research in the faculty of Medicine, University of Alberta, Canada and at the Royal Free Hospital in London.

Ajay Agrawal is a member in Public-listed Company, Immupharma plc London in London with operations in France and Switzerland. Also, member of the remuneration and audit committees. Won “the New Economy Pharmaceutical & Healthcare Awards for 2010″ for the best European drug development company, and for “best technology award” at the AIM awards, sponsored by PricewaterhouseCoopers Oct 2009. Earlier, also won “Breakthrough of the year award” on our $500 million licensing deal with Cephalon at the “European Mediscience Awards 2009.

Ajay Agrawal is also is an advisory member for Ignite Capital Inc., in relation to the best method to become publically traded, either by IPO, reverse merger or S-1 and 20F Filers. Transactions we have been involved both in the USA and offshore include LBO’s, mergers, acquisitions and restructurings of both private and public companies.Seeking undervalued assets and IP with substantial upside.

He has also participated in a diverse range of financing structures including but not limited to senior and asset based and cash flow debt, mezzanine and convertible debt and common stock/ preferred equity. We provide advices in relation to the most efficient use of capital and have access to a substantial array of capital providers: accredited investors, full service investment banking firms, commercial banks, venture capital firms, fund managers, hedge funds, SBIC’s, offshore funds, PIPE funds, family offices and private equity sponsors.

Chris Oglesby Chief Executive Officer (Bruntwood)

Bio

Chris Oglesby grew up in Manchester from the age of four, attending Cheadle Hulme School, before studying at the London School of Economics and City University, London. He graduated with a BSc (Hons) in Property Valuation and Finance and joined the investment team in the City of London Office of St Quintin (now CBRE), before returning north to work for Bruntwood in 1991. He qualified as a Chartered Surveyor in 1993 and set up Bruntwood’s Manchester city centre office, adding an in-house sales and marketing team, before taking over the reins of the company as CEO at the end of 1999.

Chris Oglesby’s company is a family-owned and run company, Bruntwood has always operated with a strong set of values, founded on its belief that the success of the company comes from the success of its customers and the communities in which it operates. This commitment to cities has led to Chris playing an active and often leading role in many public and private sector initiatives and partnerships. He has been a board member at CityCo (Manchester’s city centre management company), the Piccadilly Partnership, Corridor Manchester (the city’s major knowledge economy initiative focused on its universities and hospitals) and the Irwell City Park initiative along the boundary between Manchester and Salford. In Liverpool and Leeds, he has taken his experience of best practice in local area partnerships and instigated the set-up of the Commercial District and West End Partnerships respectively in each city.

Bruntwood is nationally recognised for its support of cultural and community initiatives, donating 10% of its annual profits to charitable causes. Chris is a Trustee of The Oglesby Charitable Trust, which works with more than 40 community based charities a year, and is a board member of Onside, a new charity which is developing a series of youth centres across the North based on the successful Lads and Girls Club model pioneered in Bolton.

Chris has a strong belief in continued personal development. He was a member of the Academy of Chief Executives from 1998-2002 and has been a member of the Young Presidents Organisation since 2000, holding several officer positions over the years including Chairman in 2007/8. He also attended the Owner President Management Programme at Harvard for three years, graduating in 2007.

Chris Oglesby, Bruntwood CEO and MSP Chairman, said:“Through our acquisition of Alderley Park, we have a unique opportunity to create a diverse innovative community of bioscience businesses which is internationally respected for the quality of its work and as a sustainable business model. With our partners and the community of exceptional scientists who choose to remain at the Park, we will build a flagship for a vibrant life sciences industry in the North of England.”

Prem Bajaj Visiting Doctor (Imperial College Healthcare NHS Trust, Charring Cross Hospital, London)

Bio

Dr. Prem Bajaj is currently Medical Director of Modern Health Limited, London. He completed MBBS from Delhi University, India, has a Fellowship of the College of General Practitioners, India, Doctor of Medicine (Copenhagen University, Denmark) Ph.D. in Pain Management (Alborg University, Denmark), Masters in Clinical Pathology and Immunology (Sheffield Medical School, UK), Masters in Pain Managment (Wales School of Medicine, Cardiff, UK) and Certifications in Medical Acupuncture and Hypnotherapy from UK. He has published articles in several international journals and is an honorary reviewer for several peer review journals. He has won several scholarships and awards during his career.

Dr. Prem Bajaj is a medical practitioner specialising in pain management, clinical pathology, acupuncture and hypnotherapy. His approach to patient management is holistic and he also incoporates medical acupuncture and CBT-hypnotherapy into the management where appropriate. He subspecialises in managing fatigue syndromes, deaddiction, chronic diseases including fibromyalgia, Lyme disease and multiple chemical sensitivities. He has also gained broad, multi-speciality experience having worked in the departments of Neurology, Orthopaedics, Medicine and Pathology in large hospitals in Denmark and India. He has done his post-doctoral clinical research from the department of Addiction Pharmacology, San Francisco, USA .

Dr. Prem Bajaj is fluent in English, Danish, Hindi and Punjabi.

Dr. Prem Bajaj’s special strengths are that he is able to establish a special comfort zone with his patients and reaches the depth of their problems, providing them appropriate treatment and educating them to follow the principle ”prevention is better than cure”. His approach is full of empathy, sympathy and is non-judgemental.

His values are that he is truthful, honest and delivers with self clarity. He is an academic researcher, an expert in conducting clinical trials, a social worker, author, reviewer of scientific publications and also possess an indepth knowledge of drug development, drug safety and Good Medical Practices.

My Vision: To use my broad spectrum medical and clinical skills in the prevention and management of complex diseases and bringing goodness, happiness, good health and peace to all.

Ravi Dugal President (Flipick Pvt. Ltd.)

Bio

Ravi Dugal, President of Flipick Pvt. Ltd. (www.flipick.com), a self-catering online service that allows publishers and design shops to produce their own fixed-format eBooks directly from within Adobe InDesign.

Flipick is a technology-based partner that provides interactive, real time, self-paced ecosystems for learning and managed technical services. It helps create an immersive environment that is conducive to conceptual learning. Flipick delivers a 360° solution for the educational industry that includes content digitisation, re-authoring, interactive designs, game based eLearning, assessment and detailed analytics as well as content delivery on web, iOS, Android and Windows 8 platforms.

Some of the services include:

₋ Technical Need Analysis

₋ Building interactive content for higher education

₋ Authoring content for HTML5 based 2D/3D animation

₋ Re-authoring animations from Flash to HTML5

₋ Video production and enhancementsFounder Abacus Computers Limited the first in India to pioneer a revolution for open platform language publishing and newspaper editorial system in the eightees

Other experiences;

CEO of Mediawide group of companies. Pioneered self service real estate advertising solutions for UK newspapers almost 8 years ago. Solutions are used in leading newspapers today, one of the newspaper chain building almost 4000 broadsheet real estate pages every month

Architect of Brandmark, a unique solution for localized marketing for leading brands. Brandmark comprises media planning, ad building, automated adaptations, approvals management and electronic delivery. Leading brands including Singapore Airlines, Standard Chartered Bank, Hyatt, Monsanto, Goodyear, Shell and Wriggleys use the solution to build print ads, catalogs, flip books, web banners and visual merchandize

Vertical solutions of Brandmark include workflow and FSI (circulars) builder with full support of versions for regional promotions

Mediawide is actively involved in consulting and bespoke development around web to print, VDP, database publishing and integration with ERP systems

Specialties: Dynamic publishing, editorial systems, advertising solutions, brand marketing operations management and language publishing

Rajay Narain Director, Global Health Alliance. Clinical, Research & Sports Cardiologist, (St George's University Hospital)

Bio

Dr Rajay Narain is a Research Cardiologist at St George’s University Hospital, London UK.

Dr Rajay Narain has been instrumental in designing the Foundation training program for Junior Doctors in the West Midlands in the UK. He has also lead MRCP exam teaching at various UK hospitals.He has been performing Coronary angiograms, echocardiograms & doing pacemakers independently as part of his training. He also runs Inherited Heart Diseases clinic at a University teaching hospital in London. He has also been associated with coronary angioplasty programs at UK’s two biggest Heart Centers.

Dr Rajay Narain has been involved in Heart Screening programs since 2005 at National & International level; he has also been screening UK Football & Rugby league players. Dr Narain while pursuing his career in Cardiology in UK also set up first of its kind of Foundation for the underprivileged in India. Dr Narain was appointed as Founder Member of International Development Group of NHS, UK & Director, Heart Foundation, UK in recognition of his contribution to International Health arena. He is also Advisor to many Government and Private Medical Institutions in India. He has presented papers at several National & International Conferences. He has to his credit publications & research projects in Cardiology which have been published in different medical journals.

Cardiologist with expertise in:
Executive Health and Heart Screening
Sports Cardiology
www.heart-matters.net

Director
Global Health Alliance
(Up-to-Date Certified Health Education & Training Courses for Health Professionals in UK & Worldwide)

Global Health Alliance is an initiative which is aimed at delivering up-to-date short accredited courses and programs for health professionals. The team consists of experts from renowned universities and hospitals from across the UK. The courses are meant for doctors, nurses, specialist nurses, paramedics, cardiac physiologists & general public.

Abhijit Mukhopadhyay President (Legal) & General Counsel at Hinduja Group (Hinduja Group)

Bio

Abhijit Mukhopadhyay has done Graduations in Commerce (Honours) and Law from India and the UK. He is a qualified Company Secretary from India and Chartered Secretary from the UK and is a Fellow Member of The Institute of Company Secretaries of India and The Institute of Chartered Secretaries and Administrators, UK.

Abhijit worked in India as Head of Legal and Company Secretary in six big public and private sector / multinational companies as Chief General Manager, Director and Senior Vice President (one step below Board level). Currently working as the President (Legal) and Company Secretary in Hinduja Group in London, ,Abhijit is involved in the Group’s worldwide legal matters covering international mediation/ arbitration, international litigation, strategic alliances, compliance of international sanctions, corporate governance and Board / Shareholder related issues, Intellectual Property Rights, M&A, negotiating international contracts, company structuring, Joint Ventures, anti-competition, etc. Abhijit was Company Secretary of a listed limited company in the UK and is a non-executive Director in Companies in five countries (Hinduja Group is a USD 15 billion Group with 80,000 people in 40 countries engaged in automobile, foundry, lubricant, power, banking, healthcare, defence, chemicals, explosives, media and BPO, thro’ its listed public and private companies). Abhijit is involved with many international organizations in various capacities as detailed below. Abhijit speaks in many international seminars globally and has written many articles in reputed international magazines.

In India, he was associated with the activities of apex Chambers of Commerce as Committee Members, Member of the Secretarial Standards Board of The Institute of Company Secretaries of India and was in the Guest Faculties of several Indian Universities. In 2010 in India Abhijit was listed as one of the top 50 legal professionals and in 2013, he was a nominee of Global General Counsel of India award.

Vivek Gupta PROF. DR. VIVEK GUPTA (SENIOR INTERVENTIONAL CARDIOLOGIST INDRAPRASTHA APOLLO HOSPITALS)

Bio

Dr. Vivek Gupta

MBBS,MD, DM, FACC, FESC, FSCAI, FAPSIC, CICC, FSCI, FIEIC, FIC (France)

Dr. Vivek Gupta is a Skilled Senior Interventional Cardiologist, presently working with Indraprastha Apollo Hospitals, New Delhi and associated with Indo European Course on Revascularization IECR as Founder Scientific Chairman since its inception and also facilitating the Free Services to the poor heart patients through Charitable organization since 1996. He is also involved in heart research in collaboration with French and other European Cardiologist. He is recipient of various Fellowships including prestigious American College of Cardiology, European Society of Cardiology, Society of Cardiovascular Angiography and Interventions (SCAI, USA), Fellowship of Asian Pacific Society of Interventional Cardiology, Fellowship of Cardiological Society of India etc. Honored with Delhi Ratan award, Glory of India award, Best Citizen of India award, Leading Health Professional of world, Cambridge, UK, Mathur Vaish Samaaj Shiromani etc.

Dr. Vivek Gupta is Founder Course Chairman for International Cardiology teaching Course – Indo European Course on Revascularization (IECR) for young Interventional Cardiologist with objective for the improvement of healthcare of Indian Physicians and Cardiologist by enhancing the knowledge base of Physicians based in st Rural regions of Indian subcontinent. 1 IECR was held in Delhi nd (Jan 4-6, 2008), 2 IECR was held in London and Delhi (Nov – Dec rd 2008) and the 3 IECR was held in Paris (Nov 3-4, 2009) followed by th Indian Chapter in Delhi on Dec 20-21, 2009. The 4 IECR was organized in Amsterdam (August 24-26, 2010) in Academic Medical Centre with huge participation and record 13 Live Transmissions. It also had European Board of Cardiology accreditation and th Collaboration of American College of Cardiology. 5 IECR was held in th Rome on Nov 29 , 2011 with Japanese and European participation. th 6 IECR was successfully accomplished in Zurich on Nov 21-22, 2012 with live transmissions and lectures. IECR is also planning to educate the Doctors based in the Rural India for the enhancement of their knowledge with the aim of improving the healthcare of India. Dr Vivek Gupta and IECR has got special recognition and applause from world Cardiology community. Dr. Gupta is also, Founder Director of Indo-European Interventional Council (IEIC) providing Research and training for Cardiologist globally. Foreign medical Students from France and other European Countries join Dr. Gupta regularly. Dr. Gupta is often referred as the bridge between European and Indian Cardiologists.

Ayad Abdul-Ahad Vice President, General Medicine, Global Product Development (PPD)

Bio

Ayad Abdul-Ahad specialises in Biotechnology, Drug Development, Medical Affairs, Clinical Immunology, CNS, Neurodegenerative Disorders, Multiple Sclerosis, Oncology, Hematology, Pain, Medical Affairs change management, optimisation and re-organisation.

Ayad Abdul-Ahad suggests that Clinical studies offer a unique opportunity to assess the frequency and severity of treatment-emergent adverse events (TEAEs) in a controlled and objective setting. Data from clinical studies is one of the most important pieces of information available to physicians and patients to determine the choice of treatment.

75% of outpatients desired to be told of every single possible TEAE associated with their medication. Clinically meaningful assessment of the tolerability is important, as it may have a negative impact compliance with treatment, and patient quality of life. However, detailed safety discussion may be frequently under-represented and the quality and quantity of safety reporting across a range of studies has been found to be inadequatey.

A substantial amount of detailed information on the incidence and presence of TEAEs is recorded clinical studies. TEAEs are classified into, common, serious, unexpected, of special interest and drug-related effects, As well as severity grades such as mild, moderate, severe, life threatening or mortality.

Clinical studies offer a unique opportunity to assess the frequency and severity of treatment-emergent adverse events (TEAEs) in a controlled and objective setting. Data from clinical studies is one of the most important pieces of information available to physicians and patients to determine the choice of treatment.

75% of outpatients desired to be told of every single possible TEAE associated with their medication. Clinically meaningful assessment of the tolerability is important, as it may have a negative impact compliance with treatment, and patient quality of life. However, detailed safety discussion may be frequently under-represented and the quality and quantity of safety reporting across a range of studies has been found to be inadequatey.

A substantial amount of detailed information on the incidence and presence of TEAEs is recorded clinical studies. TEAEs are classified into, common, serious, unexpected, of special interest and drug-related effects, As well as severity grades such as mild, moderate, severe, life threatening or mortality.

ABOUT THE EVENT

Tickets

sponsors

GET IN TOUCH

Get in touch

Past events

Trading India – Connecting India and global derivatives markets

Education Innovation Conference 2017 (EIC2017 Pune)

bioConclave 2017

Education Innovation Conference 2017 (EIC2017)

Corporate Legal Innovators 2016

bioConclave 2016

Education Innovation Conference 2016

Corporate Legal Innovators 2015

bioConclave 2015